Chengjun Sui
Impact in
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Research top 5%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
Papers in
-
- Circular RNAs in diseases 9
- RNA modifications and cancer 6
-
- MicroRNA in disease regulation 13
- Cancer-related molecular mechanisms research 10
- Co-authors
- Yanming Zhou (14 shared papers)Jiamei Yang (19 shared papers)Weifeng Shen (12 shared papers)Jiamei Yang (12 shared papers)Jiongjiong Lu (10 shared papers)Binghua Dai (17 shared papers)Zhengfeng Yin (3 shared papers)Bin Li (5 shared papers)
- Journals
- Advanced Science (3 papers)Cancer Letters (2 papers)World Journal of Surgical Oncology (2 papers)Annals of Surgical Oncology (2 papers)Tumor Biology (2 papers)
- Partner nations
- ChinaItalyUnited States
In The Last Decade
Chengjun Sui
54 papers receiving 1.5k citations
Peers
Comparison fields: 5 of 78
- Hepatology 362
- Cancer Research 625
- Oncology 495
- Surgery 449
- Molecular Biology 679
Countries citing papers authored by Chengjun Sui
This map shows the geographic impact of Chengjun Sui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chengjun Sui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chengjun Sui more than expected).
Fields of papers citing papers by Chengjun Sui
This network shows the impact of papers produced by Chengjun Sui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chengjun Sui. The network helps show where Chengjun Sui may publish in the future.
Co-authors
The 25 scholars most cited alongside Chengjun Sui, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 58 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 93 | |
| 2 | 2010 | 92 | |
| 3 | 2016 | 85 | |
| 4 | 2009 | 85 | |
| 5 | 2020 | 81 | |
| 6 | 2012 | 77 | |
| 7 | 2011 | 71 | |
| 8 | 2014 | 57 | |
| 9 | 2011 | 57 | |
| 10 | 2015 | 52 | |
| 11 | 2012 | 45 | |
| 12 | 2020 | 43 | |
| 13 | 2022 | 36 | |
| 14 | 2019 | 34 | |
| 15 | 2011 | 34 | |
| 16 | 2018 | 31 | |
| 17 | 2015 | 29 | |
| 18 | MicroRNA-147 suppresses human hepatocellular carcinoma proliferation migration and chemosensitivity by inhibiting HOXC6. | 2016 | 29 |
| 19 | 2017 | 26 | |
| 20 | 2021 | 26 |
About Chengjun Sui
Chengjun Sui is a scholar working on Molecular Biology, Cancer Research, Surgery, Oncology and Hepatology, having authored 58 papers that have together received 1.5k indexed citations. Recurring topics across this work include Cholangiocarcinoma and Gallbladder Cancer Studies (18 papers), Hepatocellular Carcinoma Treatment and Prognosis (17 papers), MicroRNA in disease regulation (13 papers), Cancer-related molecular mechanisms research (10 papers), Circular RNAs in diseases (9 papers), Gallbladder and Bile Duct Disorders (7 papers), Pancreatic and Hepatic Oncology Research (7 papers) and RNA modifications and cancer (6 papers). The work is most often cited by research in Hepatology (362 citations), Cancer Research (625 citations), Oncology (495 citations), Surgery (449 citations) and Molecular Biology (679 citations). Chengjun Sui has collaborated with scholars based in China, Italy and United States. Frequent co-authors include Yanming Zhou, Jiamei Yang, Weifeng Shen, Jiamei Yang, Jiongjiong Lu, Binghua Dai, Zhengfeng Yin, Bin Li, Geng Li and Shuangjia Wang. Their work appears in journals such as Advanced Science, Cancer Letters, World Journal of Surgical Oncology, Annals of Surgical Oncology and Tumor Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.